Australia markets closed

Eagle Pharmaceuticals, Inc. (EGRX)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
26.05+0.23 (+0.89%)
At close: 04:00PM EDT
26.05 0.00 (0.00%)
After hours: 04:02PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 349.65M
Enterprise value 366.68M
Trailing P/E 14.87
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)1.25
Price/book (mrq)1.47
Enterprise value/revenue 1.35
Enterprise value/EBITDA 7.87

Trading information

Stock price history

Beta (5Y monthly) 0.74
52-week change 3-53.75%
S&P500 52-week change 3-14.73%
52-week high 357.94
52-week low 324.35
50-day moving average 333.26
200-day moving average 343.51

Share statistics

Avg vol (3-month) 3167.48k
Avg vol (10-day) 3200.49k
Shares outstanding 513.28M
Implied shares outstanding 6N/A
Float 811.7M
% held by insiders 111.99%
% held by institutions 189.06%
Shares short (14 Sept 2022) 4701.44k
Short ratio (14 Sept 2022) 44.2
Short % of float (14 Sept 2022) 49.70%
Short % of shares outstanding (14 Sept 2022) 45.28%
Shares short (prior month 14 Aug 2022) 4820.9k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 June 2022


Profit margin 8.37%
Operating margin (ttm)21.22%

Management effectiveness

Return on assets (ttm)11.17%
Return on equity (ttm)10.53%

Income statement

Revenue (ttm)272.18M
Revenue per share (ttm)21.13
Quarterly revenue growth (yoy)54.10%
Gross profit (ttm)129.37M
Net income avi to common (ttm)22.79M
Diluted EPS (ttm)1.86
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)36.56M
Total cash per share (mrq)2.75
Total debt (mrq)53.59M
Total debt/equity (mrq)22.52
Current ratio (mrq)1.78
Book value per share (mrq)17.93

Cash flow statement

Operating cash flow (ttm)35.53M
Levered free cash flow (ttm)17.53M